Skip to main content
Clinical Trials/NCT05396287
NCT05396287
Active, not recruiting
Not Applicable

The Impact of Cerebral Anatomical Variations on Cerebrovascular Reactivity

University of Wisconsin, Madison1 site in 1 country80 target enrollmentJuly 19, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Brain Blood Flow
Sponsor
University of Wisconsin, Madison
Enrollment
80
Locations
1
Primary Endpoint
Cerebral Vascular Reactivity to Hypercapnia
Status
Active, not recruiting
Last Updated
9 months ago

Overview

Brief Summary

Brain blood flow regulation will be measured in response to environmental changes using MRI.

Detailed Description

Global brain blood flow decreases with advancing age; however, some adults have accelerated declines in brain blood flow, placing them at a greater risk of cognitive impairment. Similarly, brain reactivity to increased levels of carbon dioxide decreases with age, with a greater decline in adults with vascular risk factors and is impaired in early Alzheimer's disease. Preclinical models suggest that reduced brain blood flow, results in low levels of oxygen regionally. Currently, there are a lack of human studies that investigate the cause or consequence of altered blood flow regulation in the brain. The research aims are: 1. Determine the impact of vertebral artery hypoplasia (VAH) on brain reactivity to increased levels of carbon dioxide. 2. Determine the impact of VAH on the brain blood flow response to acute low levels of oxygen.

Registry
clinicaltrials.gov
Start Date
July 19, 2022
End Date
July 1, 2026
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • BMI ≤38.5 kg/m2
  • Nonsmoker
  • Female subjects: postmenopausal
  • Currently enrolled in the Wisconsin Alzheimer's Disease Research Clinical Core

Exclusion Criteria

  • Diagnosis of mild cognitive impairment or Alzheimer's disease
  • Uncontrolled hypertension
  • History or evidence of hepatic disease, hematological disease, or peripheral vascular disease
  • Severe kidney injury requiring hemodialysis
  • Cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia
  • History of clinically significant ischemic or hemorrhagic stroke, or significant cerebrovascular disease
  • History of HIV/AIDS
  • Severe untreated obstructive sleep apnea
  • History of diabetes with HbA1c greater than 9.5%
  • Major neurologic disorders other than dementia (e.g., multiple sclerosis, amyotrophic lateral sclerosis, brain surgery, etc.)

Outcomes

Primary Outcomes

Cerebral Vascular Reactivity to Hypercapnia

Time Frame: One study visit, up to 120 minutes in the MRI

The change in brain blood flow using MRI will be measured in response to a hypercapnic breathing test. The participants cerebral vascular reactivity to hypercapnia will be compared between the controls (without VAH) and those with VAH.

Cerebral Blood Flow Response to Hypoxia

Time Frame: One study visit, up to 120 minutes in the MRI

The change in brain blood flow using MRI will be measured in response to a hypoxic breathing test. The participants cerebral blood flow response to hypoxia will be compared between the controls (without VAH) and those with VAH.

Study Sites (1)

Loading locations...

Similar Trials